Skip to content
drillr.ai

HCWB

HCW Biologics Inc.

NASDAQ · USHealthcareBiotechnology
$3.83-4.25%

Price as of Jul 20, 2026

HCWB news

HCW Biologics Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

    MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Mar

    Globe Newswire ·

  2. HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

    Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings Panel MIRAMAR, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic

    Globe Newswire ·

  3. HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

    Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”)

    Globe Newswire ·

  4. E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

    NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (https://www.globenewswire.com/Tracker?data=tc2GGNVHLjjF_rzrtO4o_9pi4nTdxga_pzczbIcF6Hd5x93bjQOByexx9ZWOBYzKr9aDOBaqJWDV7a4BbNoL0CSaP62KRVQVyt10IIfYaJ8=) (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a

    Globe Newswire ·

  5. HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

    MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-associated dysplasia, today announced the pricing of its private placement of an aggregate of 2,846,975 units at a purchase price of $1.405 per unit priced at-the-market under Nasdaq rules to a group of healthcare investors (the “Investors”).

    Globe Newswire ·

  6. HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

    MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two do

    Globe Newswire ·

  7. HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

    MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced that the Company’s Special Meeting of Stockholders, held on April 27, 2026, at 10:00 a.m. Eastern Time (“Special Meeting”) was adjourned, without any business being conducted, due to lack of the required qu

    Globe Newswire ·

  8. HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead prod

    Globe Newswire ·

  9. HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

    Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027 HCW Biologics has “free” option to reclaim the rights to the Americas territory MIRAMAR, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based commercial- and clinical-stage

    Globe Newswire ·